Immune-enhancing composition comprising fermented sipjeondaebo-tang as effective component

A fermented Sipjeondaebotang extract, prepared through dual fermentation with Saccharomyces cerevisiae and Bacillus, effectively enhances immune responses by increasing cytokine secretion and NK cell activity, addressing the lack of effective immunostimulants in existing compositions.

KR103044795B1Active Publication Date: 2026-11-10NANUM PHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240042536
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-03-28
Filing Date
2024-03-28
Publication Date
2026-11-10
Estimated Expiration
2044-03-28

AI Technical Summary

Technical Problem

There is a limited number of immunostimulants available for human use that effectively enhance immune responses without side effects, and existing compositions for immune enhancement, such as fermented Samultang and beet extract, do not include fermented Sipjeondaebotang as an active ingredient.

Method used

A health functional food, quasi-drug, and veterinary composition are developed using a fermented Sipjeondaebotang extract, prepared by primary fermentation with Saccharomyces cerevisiae and secondary fermentation with Bacillus, to enhance immune responses by increasing cytokine secretion and NK cell activity.

Benefits of technology

The fermented Sipjeondaebotang extract significantly increases cytokine secretion and enhances NK cell activity, providing effective immune enhancement compared to unfermented Sipjeondaebotang and single-fermentation products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024034924686-PAT00001_ABST
    Figure 112024034924686-PAT00001_ABST
Patent Text Reader

Abstract

The present invention relates to an immune-boosting composition containing a fermented Sipjeondaebo-tang as an active ingredient. More specifically, the fermented Sipjeondaebo-tang prepared by inoculating Saccharomyces cerevisiae strain into Sipjeondaebo-tang for primary fermentation, and then inoculating Bacillus sp. strain for secondary fermentation, has an excellent effect of increasing the amount of cytokines secreted by spleen cells and enhancing the activity of NK cells compared to Sipjeondaebo-tang before fermentation; Sipjeondaebo-tang prepared by inoculating Saccharomyces cerevisiae strain; and Sipjeondaebo-tang prepared by inoculating Bacillus sp. strain. Therefore, it can be usefully used in health functional foods, quasi-drugs, feed additives, etc., for immune enhancement.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to an immune-enhancing composition containing a fermented Sipjeondaebotang extract as an active ingredient. Background Technology

[0002] An immune response is a self-defense system existing within a host, a biological phenomenon in which it distinguishes and eliminates various substances or organisms invading from the outside by distinguishing them from itself. This surveillance system for self-defense is carried out through two main mechanisms: humoral immunity and cellular immunity. Immunostimulation refers to any action that enhances these specific or non-specific, cellular, and humoral immune responses of the host; it has recently garnered significant attention as it is being utilized in the treatment of infections and tumors.

[0003] In other words, by improving immunosuppressive states and enhancing immune activity, it is possible to apply this to the treatment of various diseases. However, due to various side effects such as inherent toxicity and differences in immune responses, the number of known immunostimulants currently available for human use is extremely limited, and their efficacy is known to be very minimal. Therefore, while there is a growing need to develop natural substances that exhibit useful immune-enhancing effects without side effects, research in this area remains insufficient.

[0004] Meanwhile, Sipjeondaebotang refers to a herbal decoction of Korean origin that possesses the efficacy of "Sipjeon" (all ten aspects), and is used to greatly nourish the body when general weakness is severe following various chronic or serious illnesses, and when Qi and blood, Yin and Yang, the exterior and interior, and the internal and external aspects are all deficient. The aforementioned Sipjeondaebotang may be prepared according to the manufacturing method of Sipjeondaebotang traditionally used in Korean medicine, and its constituent herbal ingredients include ginseng (as disclosed in the Standards for Crude Drugs of Herbal Medicines Outside the Korean Pharmacopoeia). Panax ginseng CA Meyer), Atractylodes ( Atractylodes japonica Koidz.), Poria cocos ( Poria cocos Wolf), Angelica ( Angelica gigas Nakai), Heavenly Palace ( Cnidium officinale Makino), Rehmannia glutinosa ( Rehmannia glutinosa ), ginger( Zingiber officinale Roscoe), jujube ( Zizyphus jujube var. inermis Mill.), peony ( Paeonia lactiflora Pall.), Astragalus ( Astragalus membranaceus Bunge), broiler chicken ( Cinnamomum cassia Blume.) and licorice ( Glycyrrhiza glabra Includes L.)

[0005] Regarding prior art related to immune enhancement, Korean Registered Patent No. 1787337 discloses "a method for preparing fermented Samultang having antioxidant and immune efficacy and fermented Samultang according thereto," and Korean Published Patent No. 2022-0094940 discloses "a composition for immune enhancement containing a fermented product of beet extract." However, there has not yet been any disclosure regarding the "composition for immune enhancement containing a fermented product of Sipjeondaebotang as an active ingredient" of the present invention. The problem to be solved

[0006] The present invention is derived from the above-mentioned requirements, and the present invention provides an immune-enhancing composition containing a fermented Sipjeondaebotang as an active ingredient, and more specifically, Saccharomyces cerevisiae ( Saccharomyces cerevisiae After inoculating with a ) strain and performing primary fermentation, Bacillus genus ( Bacillus The present invention was completed by confirming that the Sipjeondaebotang fermented product of the present invention, prepared by secondary fermentation by inoculating a strain of Saccharomyces sp.) and compared with the Sipjeondaebotang before fermentation; the Sipjeondaebotang fermented product prepared by inoculating a strain of Saccharomyces cerevisiae; and the Sipjeondaebotang fermented product prepared by inoculating a strain of Bacillus genus, has an excellent effect in increasing the amount of cytokine secretion in splenic cells and enhancing the activity of NK cells. means of solving the problem

[0007] To solve the above problem, the present invention provides a health functional food composition for immune enhancement containing a fermented Sipjeondaebotang extract as an active ingredient.

[0008] In addition, the present invention provides an immune-boosting quasi-drug containing a fermented Sipjeondaebotang extract as an active ingredient.

[0009] In addition, the present invention provides an immune-boosting feed additive containing a fermented Sipjeondaebotang extract as an active ingredient.

[0010] In addition, the present invention provides a veterinary composition for immune enhancement containing a fermented Sipjeondaebotang extract as an active ingredient. Effects of the invention

[0011] The present invention relates to an immune-enhancing composition containing a fermented Sipjeondaebotang extract as an active ingredient, and more specifically, to a composition containing Saccharomyces cerevisiae ( Saccharomyces cerevisiae After inoculating with a ) strain and performing primary fermentation, Bacillus genus ( Bacillus The Sipjeondaebotang fermented product of the present invention, prepared by secondary fermentation by inoculating a strain of Saccharomyces sp.) and a Sipjeondaebotang fermented product prepared by inoculating a strain of Saccharomyces cerevisiae and a strain of Bacillus, has an excellent effect of increasing the amount of cytokine secretion in splenic cells and enhancing the activity of NK cells compared to Sipjeondaebotang before fermentation; Sipjeondaebotang fermented product prepared by inoculating a strain of Saccharomyces cerevisiae; and Sipjeondaebotang fermented product prepared by inoculating a strain of Bacillus. Brief explanation of the drawing

[0012] Figure 1 shows the results of confirming the IL-2 secretion amount of spleen cells treated with Sipjeondaebotang fermented product. Normal is the normal group with no treatment, and ConA (Concanavalin A, 1 μg / ml) is the positive control group. ### indicates that the IL-2 content of the positive control group significantly increased compared to the normal group, with p<0.001. *, **, and *** indicate that the IL-2 content of the Sipjeondaebotang (400 μg / ml) treatment group before fermentation, the Sipjeondaebotang fermented product prepared by yeast fermentation (200, 400 μg / ml) treatment group, the Sipjeondaebotang fermented product prepared by Bacillus fermentation (200, 400 μg / ml) treatment group, or the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation (200, 400 μg / ml) treatment group was significantly increased compared to the positive control group, with * being p<0.05, ** being p<0.01, and *** being p<0.001. $$ indicates that at a treatment concentration of 400 μg / ml, the IL-2 content of the group treated with Sipjeondaebotang produced by yeast / Bacillus fermentation was significantly higher compared to the group treated with Sipjeondaebotang before fermentation or the group treated with Sipjeondaebotang produced by yeast fermentation, with p<0.01. @@@ indicates that at a treatment concentration of 200 μg / ml, the IL-2 content of the group treated with Sipjeondaebotang produced by yeast / Bacillus fermentation was significantly higher compared to the group treated with Sipjeondaebotang before fermentation, the group treated with Sipjeondaebotang produced by yeast fermentation, or the group treated with Sipjeondaebotang produced by Bacillus fermentation, with p<0.001. & indicates that the IL-2 content of the Sipjeondaebo-tang fermented product prepared by yeast / Bacillus fermentation was significantly higher compared to the Sipjeondaebo-tang fermented product prepared by Bacillus fermentation at a treatment concentration of 400 μg / ml, with p<0.05. Figure 2 shows the results of confirming the IL-10 secretion of spleen cells by treatment with Sipjeondaebotang fermented product. Normal is the normal group with no treatment, and ConA (Concanavalin A, 1 μg / ml) is the positive control group. # indicates that the IL-10 content of the positive control group significantly increased compared to the normal group, with p<0.05. * indicates that the IL-10 content of the group treated with Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation significantly increased compared to the positive control group, with p<0.05. Figure 3 shows the results of confirming the effect of increasing NK cell activity by administering Sipjeondaebotang fermented extract. (A) is an effector cell to target cell (E:T) ratio of 25:1, and (B) is an effector cell to target cell (E:T) ratio of 50:1. Normal is the normal group with no treatment, and PC is the positive control group administered red ginseng. ** and *** indicate that the NK cell activity of the positive control group or the group administered with Sipjeondaebotang fermented extract prepared by yeast / Bacillus fermentation was statistically significantly increased compared to the normal group, with ** being p<0.01 and *** being p<0.001. Figure 4 shows the results confirming the effect of increasing B cell activity by administering Sipjeondaebotang fermented extract. Normal is the normal group that received no treatment, and PC is the positive control group administered red ginseng (200 mg / kg). *, ** represent the CD23 levels of the positive control group or the group administered with Sipjeondaebotang fermented extract prepared by yeast / Bacillus fermentation, compared to the normal group. + / B220 + This indicates that the absolute number of cells increased statistically significantly; * is p<0.05 and ** is p<0.01. Specific details for implementing the invention

[0013] To achieve the objective of the present invention, the present invention provides a health functional food composition for immune enhancement containing a fermented Sipjeondaebotang extract as an active ingredient.

[0014] The above-mentioned Sipjeondaebotang fermented product may be prepared by a method including the following steps, but is not limited thereto:

[0015] 1) A step of preparing Sipjeondaebotang by adding water to a mixture of Angelica gigas, Panax ginseng, Rehmannia glutinosa, Poria cocos, Astragalus membranaceus, Paeonia lactiflora, Cinnamomum cassia, Glycyrrhiza glabra, Cnidium officinale, Atractylodes macrocephala, Jujube, and ginger, and performing hot water extraction;

[0016] 2) Saccharomyces cerevisiae ( Saccharomyces cerevisiae A step of primary fermentation by inoculating a ) strain; and

[0017] 3) After primary fermentation in step 2) above, Bacillus genus ( Bacillus A step of secondary fermentation by inoculating with a sp.) strain.

[0018] In one embodiment of the present invention, the Sipjeondaebotang may be prepared by adding water to a mixture of 1 to 8 parts by weight of Angelica gigas, 1 to 8 parts by weight of Panax ginseng, 1 to 8 parts by weight of Rehmannia glutinosa, 1 to 8 parts by weight of Poria cocos, 1 to 8 parts by weight of Astragalus membranaceus, 1 to 8 parts by weight of Paeonia lactiflora, 1 to 8 parts by weight of Cinnamomum cassia, 1 to 8 parts by weight of Glycyrrhiza glabra, 1 to 8 parts by weight of Cnidium officinale, 1 to 8 parts by weight of Atractylodes macrocephala, 1 to 8 parts by weight of Jujube, and 0.5 to 5 parts by weight of ginger, and by hot water extraction; preferably, the Sipjeondaebotang may be prepared by adding water to a mixture of 4 parts by weight of Angelica gigas, 4 parts by weight of Panax ginseng, 4 parts by weight of Rehmannia glutinosa, 4 parts by weight of Poria cocos, 4 parts by weight of Astragalus membranaceus, 4 parts by weight of Paeonia lactiflora, 4 parts by weight of Cinnamomum cassia, 4 parts by weight of Glycyrrhiza glabra, 4 parts by weight of Atractylodes macrocephala, 4 parts by weight of Jujube, and 1 part by weight of ginger, and by hot water extraction. It is not limited to this.

[0019] In step 2) above, the Saccharomyces cerevisiae strain may be the Saccharomyces cerevisiae MAB Y1 strain with accession number KCTC 11386BP, but is not limited thereto.

[0020] In step 3) above, the Bacillus strain may be the Bacillus strain MAB08 with deposit number KCTC 11264BP, but is not limited thereto.

[0021] In step 2) above, fermentation is preferably carried out at 30 to 37°C for 1 to 5 days, and more preferably at 30°C for 3 days, but is not limited thereto.

[0022] In step 3) above, fermentation is preferably carried out at 30 to 37°C for 1 to 5 days, and more preferably at 37°C for 3 days, but is not limited thereto.

[0023] The above composition may be prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto.

[0024] When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately used according to its intended purpose. Generally, when manufacturing food or beverages, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, relative to the total raw materials. However, in the case of long-term consumption for health purposes, the above amount may be less than the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range.

[0025] There are no special restrictions on the types of the above-mentioned health functional foods. Examples of foods to which the above-mentioned health functional food composition may be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea drinks, alcoholic beverages, and vitamin complexes, and include all health foods in the conventional sense.

[0026] In addition, the health functional food composition of the present invention may be manufactured into a food, particularly a functional food. The functional food of the present invention includes ingredients that are typically added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, and flavoring agents. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredients. The natural carbohydrate is preferably a monosaccharide (e.g., glucose, fructose, etc.), a disaccharide (e.g., maltose, sucrose, etc.), an oligosaccharide, a polysaccharide (e.g., dextrin, cyclodextrin, etc.), or a sugar alcohol (e.g., xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., taumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

[0027] In addition to the above health functional food composition, it may further contain various nutritional agents, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Although the proportion of these added ingredients is not of great importance, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food composition of the present invention.

[0028] In addition, the present invention provides an immune-boosting quasi-drug containing a fermented Sipjeondaebotang extract as an active ingredient.

[0029] The term "quasi-drug" used in the present invention refers to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases of humans or animals, and which have a milder effect than pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are defined as articles excluding those used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases of humans or animals, or products that have a mild effect on the human body or do not act directly on it.

[0030] The quasi-drug of the present invention is used for the purpose of boosting immunity, and there are no particular limitations on its formulation. In each formulation, other ingredients may be arbitrarily selected and combined according to the formulation or purpose of use of other quasi-drugs. The amount of active ingredients mixed may be appropriately determined according to the purpose of use (inhibition or alleviation). For example, it may include conventional adjuvants such as thickeners, stabilizers, solubilizers, vitamins, pigments, and fragrances, and carriers.

[0031] In addition, the present invention provides an immune-boosting feed additive containing a fermented Sipjeondaebotang extract as an active ingredient.

[0032] The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act. In the present invention, the term "feed" may refer to any natural or artificial prescribed food, single meal, etc., or the components of said single meal, intended for or suitable for animals to eat, consume, and digest. The types of said feed are not particularly limited, and feeds commonly used in the relevant technical field may be used. Non-limiting examples of said feed include plant-based feeds such as grains, root vegetables, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal-based feeds such as proteins, inorganic substances, oils and fats, minerals, single-cell proteins, zooplankton, or food waste. These may be used individually or in a mixture of two or more types.

[0033] In addition, the present invention provides a veterinary composition for immune enhancement containing a fermented Sipjeondaebotang extract as an active ingredient.

[0034] The veterinary composition containing the Sipjeondaebotang fermented product of the present invention may further include appropriate excipients and diluents according to conventional methods. Examples of excipients and diluents that may be included in the veterinary composition containing the Sipjeondaebotang fermented product of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.

[0035] The veterinary composition containing the fermented Sipjeondaebotang according to the present invention may further include a filler, an anticoagulant, a lubricant, a humectant, a spice, an emulsifier, a preservative, etc. The veterinary composition according to the present invention may be formulated using methods well known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of a powder, granule, tablet, capsule, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, suppository, sterile injectable solution, sterile external preparation, etc.

[0036] The veterinary composition according to the present invention may be administered once or several times a day, depending on the age, sex, and weight of the animal, and the dosage may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, etc. Accordingly, the above dosage does not limit the scope of the present invention in any way.

[0037] The present invention will be described in detail below by way of embodiments. However, the following embodiments are merely illustrative of the present invention, and the content of the present invention is not limited to the following embodiments.

[0038] Example 1. Preparation of Sipjeondaebotang fermented product

[0039] Sipjeondaebotang was prepared by adding 855 ml of distilled water to 4 g of Angelica gigas, 4 g of Panax ginseng, 4 g of Rehmannia glutinosa, 4 g of Poria cocos, 4 g of Astragalus membranaceus, 4 g of Paeonia lactiflora, 4 g of Cinnamomum cassia, 4 g of Glycyrrhiza glabra, 4 g of Ligusticum chuanxiong, 4 g of Atractylodes macrocephala, 4 g of Jujube, and 1 g of dried ginger, followed by hot water extraction at 121°C for 15 minutes. The mixture was then filtered to produce a 5% (w / v) concentration. This was diluted with distilled water at a ratio of 1:5 (v / v), inoculated with a fermentation strain, and fermented. The fermentation strain used was Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) MAB Y1(KCTC 11386BP) strain and Bacillus genus( BacillusThe strain used was sp.) MAB08 (KCTC 11264BP), and shaking liquid fermentation was carried out with an inoculation amount of 1% (v / v).

[0040] The Sipjeondaebotang fermented product prepared by yeast fermentation was obtained by inoculating the Sipjeondaebotang with the Cerevisiae MAB Y1 strain alone and fermenting it at 30°C for 3 days, the Sipjeondaebotang fermented product prepared by Bacillus fermentation was obtained by inoculating the Sipjeondaebotang with the Bacillus genus MAB08 strain alone and fermenting it at 37°C for 3 days, and the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation was obtained by inoculating the Sipjeondaebotang with the Cerevisiae MAB Y1 strain and fermenting it at 30°C for 3 days for primary fermentation, followed by inoculating it with the Bacillus genus MAB08 strain and fermenting it at 37°C for 3 days for secondary fermentation.

[0041] Example 2. Confirmation of increased cytokine content in spleen cells

[0042] Mouse spleens were excised, washed with PBS (phosphate buffered saline), and cells were released by gently pulverizing with a 5 ml disposable syringe rod piston. The isolated cell suspension was passed through a 40 μm cell strainer, washed twice with culture medium, and centrifuged at 1,000 rpm for 5 minutes. Subsequently, the cells were suspended in RBC (red blood cell) lysis buffer and treated for 10 minutes to remove red blood cells. The cells were then dispersed in RPMI (Roswell Park Memorial Institute) 1640 medium, stained with trypan blue, and the cell count was measured. 5×10⁶ 5The cells were dispensed into a 96-well plate to achieve a cell / well concentration, and the samples were treated at different concentrations (200 and 400 μg / ml). As a positive control, 1 μg / ml of Concanavalin A (Sigma-Aldrich Co.) was added and incubated for 48 hours. The culture supernatant obtained by centrifugation was then collected, and the levels of IL-2 (BioSource, USA) and IL-10 (R&D system, USA) were measured using an ELISA kit.

[0043] As a result, as disclosed in Figure 1, the IL-2 content of the positive control group (ConA) treated with concanavalin was significantly increased compared to the normal group (Normal), and the IL-2 content of the group treated with Sipjeondaebotang (400 μg / ml) before fermentation, the group treated with Sipjeondaebotang fermented product prepared by yeast fermentation, the group treated with Sipjeondaebotang fermented product prepared by Bacillus fermentation, and the group treated with Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation was statistically significantly increased compared to the positive control group. In particular, it was confirmed that the IL-2 content of the group treated with Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation according to the present invention was statistically significantly increased compared to the group treated with Sipjeondaebotang fermented product prepared by yeast fermentation and the group treated with Sipjeondaebotang fermented product prepared by Bacillus fermentation.

[0044] In addition, when the IL-10 content was measured, it was confirmed that the IL-10 content of the positive control group treated with concanavalin was significantly increased compared to the normal group, and that the IL-10 content of the group treated with the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation of the present invention was statistically significantly increased compared to the positive control group (Fig. 2).

[0045] Example 3. Confirmation of Increased NK (Natural Killer) Cell Activity

[0046] NK cell activity was measured for the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation of the present invention, which showed the best effect in increasing IL-2 and IL-10 content in splenocytes in Example 2 above.

[0047] Specifically, 8-week-old male BALB / c mice were obtained from Daehan Biolink (eumseong, Korea) and used in the experiment after acclimatizing them to a laboratory environment (room temperature 22±2℃, humidity 55±15%, 12-hour light-dark cycle) for 2 weeks. The experimental animal groups were randomly composed of a BALB / c normal group, a positive control group administered red ginseng (200 mg / kg), and a group administered a fermented Sipjeondaebotang extract prepared by yeast / Bacillus fermentation (200 mg / kg). For the experimental procedure and administration method, the mice were separated into three groups of 5 animals each and allowed to consume food and water freely. The experiment was conducted for 2 weeks via oral administration. Splenocytes isolated from mice that had completed the 2-week oral administration of the sample were used as effector cells, and YAC-1 cells were used as target cells. Splenocyte (E) suspensions were co-cultured with YAC-1 cells (T) in 96-well plates at a ratio of 25:1 (E:T) or 50:1 (E:T) and incubated in a CO2 incubator (37°C, 5% CO2) for 4 hours. The culture supernatant was mixed with LDH (lactate dehydrogenase) solution, and the absorbance was measured at 490 nm. This confirms the level at which LDH secretion increases due to increased lysis of YAC-1 cells as NK cell activity increases, and the cytotoxicity of NK cells was calculated using the following formula.

[0048] NK cell cytotoxicity (Specific lysis %) = [(experimental release-spontaneous release) / maximum release-spontaneous release] × 100.

[0049] As a result, as disclosed in Figure 3, the apoptotic ability was statistically significantly increased in the positive control group and the group administered the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation of the present invention compared to the normal group, and it was confirmed that the immune-enhancing effect was excellent by increasing the activity of NK cells similarly to the red ginseng administration group.

[0050] Example 4. CD23 in the spleen + / B220 + Confirmation of increase in immune cell count

[0051] Cell viability was measured by measuring the concentration of the generated formazan using a spectrophotometer, utilizing the conversion of tetrazolium salt (WST-1) to formazan by mitochondrial dehydrogenases within living cells. CD23 showing B cell activity following the administration of the Sipjeondaebotang fermented product (200 mg / kg) prepared by yeast / Bacillus fermentation of the present invention in the spleen of Balb / c strain mice. + / B220 + The absolute number of immune cells was measured using flow cytometry analysis (FACS).

[0052] As a result, as disclosed in Fig. 4, CD23 in the positive control group and the group administered the Sipjeondaebotang fermented product prepared by yeast / Bacillus fermentation of the present invention compared to the normal group (Normal) + / B220 + It was confirmed that the number of absolute cells increased statistically significantly.

[0053] Depository Name: Korea Research Institute of Biotechnology and Bioengineering Biological Resource Center (KCTC) Trustee Number: KCTC11264BP Date of Deposit: 2008-01-17 Depository Name: Korea Research Institute of Biotechnology and Bioengineering Biological Resource Center (KCTC) Trustee Number: KCTC11386BP Date of Deposit: 2008-09-03

Claims

Claim 1 A health functional food composition for immune enhancement containing a fermented Sipjeondaebotang as an active ingredient, wherein the fermented Sipjeondaebotang comprises: 1) a step of preparing Sipjeondaebotang by adding water to a mixture of Angelica gigas, Panax ginseng, Rehmannia glutinosa, Poria cocos, Astragalus membranaceus, Paeonia lactiflora, Cinnamomum cassia, Glycyrrhiza glabra, Cnidium officinale, Atractylodes macrocephala, Jujube, and ginger and performing hot water extraction; 2) Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) A step of inoculating a strain to perform primary fermentation; and 3) after primary fermentation in step 2), Bacillus genus ( Bacillus A health functional food composition for immune enhancement characterized by being manufactured by a manufacturing method comprising the step of inoculating a strain (sp.) and performing secondary fermentation. Claim 2 delete Claim 3 A health functional food composition for immune enhancement according to claim 1, wherein in step 1), Sipjeondaebotang is prepared by adding water to a mixture of 1 to 8 parts by weight of Angelica gigas, 1 to 8 parts by weight of Panax ginseng, 1 to 8 parts by weight of Rehmannia glutinosa, 1 to 8 parts by weight of Poria cocos, 1 to 8 parts by weight of Astragalus membranaceus, 1 to 8 parts by weight of Paeonia lactiflora, 1 to 8 parts by weight of Cinnamomum cassia, 1 to 8 parts by weight of Glycyrrhiza glabra, 1 to 8 parts by weight of Cnidium officinale, 1 to 8 parts by weight of Atractylodes macrocephala, 1 to 8 parts by weight of Jujube, and 0.5 to 5 parts by weight of ginger, and performing hot water extraction. Claim 4 An immune-boosting health functional food composition according to claim 1, characterized in that the composition is prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candies, syrups, and beverages. Claim 5 An immune-enhancing quasi-drug containing a fermented Sipjeondaebotang extract as an active ingredient, wherein the fermented Sipjeondaebotang extract comprises: 1) a step of preparing Sipjeondaebotang by adding water to a mixture of Angelica gigas, Panax ginseng, Rehmannia glutinosa, Poria cocos, Astragalus membranaceus, Paeonia lactiflora, Cinnamomum cassia, Glycyrrhiza glabra, Cnidium officinale, Atractylodes macrocephala, Jujube, and ginger and performing hot water extraction; 2) Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) A step of inoculating a strain to perform primary fermentation; and 3) after primary fermentation in step 2), Bacillus genus ( Bacillus An immune-enhancing quasi-drug characterized by being manufactured by a manufacturing method comprising the step of inoculating a strain (sp.) and performing secondary fermentation. Claim 6 An immune-enhancing feed additive containing a fermented Sipjeondaebotang as an active ingredient, wherein the fermented Sipjeondaebotang comprises: 1) a step of preparing Sipjeondaebotang by adding water to a mixture of Angelica gigas, Panax ginseng, Rehmannia glutinosa, Poria cocos, Astragalus membranaceus, Paeonia lactiflora, Cinnamomum cassia, Glycyrrhiza glabra, Cnidium officinale, Atractylodes macrocephala, Jujube, and ginger and performing hot water extraction; 2) Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) A step of inoculating a strain to perform primary fermentation; and 3) after primary fermentation in step 2), Bacillus genus ( Bacillus An immune-enhancing feed additive characterized by being manufactured by a manufacturing method comprising the step of inoculating a strain of sp.) and performing secondary fermentation. Claim 7 A veterinary medical composition for immune enhancement containing a fermented Sipjeondaebotang as an active ingredient, wherein the fermented Sipjeondaebotang comprises: 1) a step of preparing Sipjeondaebotang by adding water to a mixture of Angelica gigas, Panax ginseng, Rehmannia glutinosa, Poria cocos, Astragalus membranaceus, Paeonia lactiflora, Cinnamomum cassia, Glycyrrhiza glabra, Cnidium officinale, Atractylodes macrocephala, Jujube, and ginger and performing hot water extraction; 2) Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) A step of inoculating a strain to perform primary fermentation; and 3) after primary fermentation in step 2), Bacillus genus ( Bacillus An immune-enhancing veterinary composition characterized by being manufactured by a method comprising the step of inoculating a strain (sp.) and performing secondary fermentation.

Citation Information

Patent Citations

  • Lactic acid bacteria ferment of sipjeondaebotang having brain neuron cell-protective activity and use thereof

    KR1020130002911A

  • Composion of fermented oriental herb, method of manufacturing the same and use of the same

    KR1020230010167A